76041-73-1

Basic information

• Product Name: 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine
• Synonyms: 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine;3-Bromo-5-(trifluoromethyl)pyridin-2-ol;3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine 98%;3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine98%;3-bromo-5-(trifluoromethyl)pyridine-2-ol;3-Bromo-5-(trifluoromethyl)pyridin-2-ol, 5-Bromo-6-hydroxy-alpha,alpha,alpha-trifluoro-3-picoline;3-Bromo-5-(Trifluoromethyl)pyridin-2-ylol
• CAS NO: 76041-73-1
• Molecular Formula: C₆H₃BrF₃NO
• Molecular Weight: 241.9933296
• Product Categories: blocks;Bromides;Pyridines
• Mol File: 76041-73-1.mol

Chemical Properties

• Boiling Point: 252.7 °C at 760 mmHg
• Flash Point: 106.6 °C
• Appearance: White to yellow/Crystalline Powder
• Density: 1.876 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 8.06±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine(76041-73-1)
• EPA Substance Registry System: 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine(76041-73-1)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 76041-73-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique functional groups allow for versatile chemical reactions, making it a valuable intermediate in the synthesis of pharmaceutical and agrochemical compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine is employed as a key component in the development of new drugs. Its presence in the molecular structure can impart specific biological activities, such as anti-inflammatory and anticancer properties, which are essential for the treatment of various diseases.
Used in Drug Discovery:
3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine is utilized in drug discovery research to identify and optimize potential drug candidates. Its unique chemical structure and functional groups make it an attractive starting point for the design and synthesis of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Development:
In the agrochemical industry, 3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine is used as a building block for the synthesis of various agrochemical compounds, such as pesticides and herbicides. Its unique properties can contribute to the development of more effective and environmentally friendly agrochemicals.
Used in Biological Activity Research:
3-Bromo-2-hydroxy-5-(trifluoromethyl)pyridine is studied for its potential biological activities, including its anti-inflammatory and anticancer properties. Researchers are interested in understanding the compound's mechanism of action and exploring its potential as a therapeutic agent for various diseases.

Upstream product

• 33252-63-0 5-(trifluoromethyl)-2(1H)-pyridone 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 

Downstream Products

• 624734-26-5 tert-butyl 3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 
• 624734-27-6 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 624734-22-1 2-chloro-5-(trifluoromethyl)pyridine-3-carbonitrile 
• 71701-92-3 2-chloro-3-bromo-5-(trifluoromethyl)pyridine 
• 129904-48-9 2-hydroxy-5-(trifluoromethyl)nicotinaldehyde 
• 1391132-68-5 5-trifluoromethyl-3-vinylpyridone 
• 1391132-71-0 C₁₅H₁₄F₃NO₂S 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS

The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

2,6-Disubstituted piperiddines as modulators

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

ALKYLAMINO, ARYLAMINO, AND SULFONAMIDO CYCLOPENTYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as defined, useful as inhibitors of chlosteryl ester transfer protein.

AMINO HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II: (wherein n, R 1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33 R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or act

TETRAHYDROPYRAN HETEROCYCLIC CYCLOPENTYL HETEROARYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is further directed to compounds of the formulas: (I) (II) (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24 and R25 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.